|
| 37584293 | Molecular measurable residual disease: staring at red herrings. | Haematologica | 2024 |
| 36323295 | Lower intensity regimens for acute myeloid leukemia: opportunities and challenges. | Leuk Lymphoma | 2023 |
| 37591942 | Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis. | Leukemia | 2023 |
| 37572683 | Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. | Lancet Haematol | 2023 |
| 37873284 | Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. | bioRxiv | 2023 |
| 38092480 | Progress and challenges in the acute leukemia field. | Best Pract Res Clin Haematol | 2023 |
| 37354069 | Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study. | Am J Hematol | 2023 |
| 37254665 | Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. | Eur J Haematol | 2023 |
| 37156478 | Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 |
| 37086851 | Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. | Transplant Cell Ther | 2023 |
| 37185614 | Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. | Bone Marrow Transplant | 2023 |
| 37051756 | Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. | Haematologica | 2023 |
| 37341779 | Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. | Ann Hematol | 2023 |
| 37358260 | A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. | Cancer Discov | 2023 |
| 37263072 | Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis. | Leuk Res | 2023 |
| 36888930 | Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. | J Clin Oncol | 2023 |
| 36585394 | Top advances of the year: Leukemia. | Cancer | 2023 |
| 36732419 | Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. | Ann Hematol | 2023 |
| 36794503 | Venetoclax response prediction in acute myeloid leukemia: are we <i>Finnish</i>-ed with uncertainty? | Haematologica | 2023 |
| 36309981 | A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. | Am J Hematol | 2023 |
| 36265087 | Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. | Blood | 2023 |
| 36350312 | A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. | Clin Cancer Res | 2023 |
| 34482403 | Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. | Blood | 2022 |
| 35511730 | Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. | Blood Adv | 2022 |
| 35799207 | 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. | Mol Cytogenet | 2022 |
| 35467936 | Professional Courtesy. | Ann Intern Med | 2022 |
| 35368098 | Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. | Hematol Oncol | 2022 |
| 36517125 | Recent progress in acute leukemia and myelodysplasia. | Best Pract Res Clin Haematol | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 35902048 | Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. | Transplant Cell Ther | 2022 |
| 36225746 | Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine. | Open Forum Infect Dis | 2022 |
| 36007102 | Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. | Clin Cancer Res | 2022 |
| 35046058 | Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. | Clin Cancer Res | 2022 |
| 35007124 | Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. | J Clin Oncol | 2022 |
| 34932793 | Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. | Blood Adv | 2022 |
| 34645926 | Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. | Bone Marrow Transplant | 2022 |
| 34525179 | The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. | Blood | 2022 |
| 34753779 | Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia. | Clin Cancer Res | 2022 |
| 32203138 | Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. | Leukemia | 2021 |
| 33617672 | A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. | Am J Hematol | 2021 |
| 33531169 | The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. | Blood Rev | 2021 |
| 34610123 | Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. | Blood Adv | 2021 |
| 34389272 | SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML. | Clin Lymphoma Myeloma Leuk | 2021 |
| 34043455 | Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. | J Clin Oncol | 2021 |
| 33406488 | NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. | J Natl Compr Canc Netw | 2021 |
| 33375853 | The propriety of upgrading responses to venetoclaxâ¿¿+â¿¿azacitidine in newly diagnosed patients with acute myeloid leukemia. | Leuk Lymphoma | 2021 |
| 33028621 | The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. | Cancer Discov | 2021 |
| 33220019 | Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. | Int J Lab Hematol | 2021 |
| 33024987 | Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. | Blood | 2021 |
| 33155727 | MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. | J Leukoc Biol | 2021 |